Dichotic Listening as a Predictor of Medication Response in Depression
| Status: | Completed |
|---|---|
| Conditions: | Depression, Depression, Major Depression Disorder (MDD), Endocrine |
| Therapuetic Areas: | Endocrinology, Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 10/14/2017 |
| Start Date: | April 1994 |
| End Date: | June 2011 |
Dichotic Listening as a Predictor of Placebo and Medication Response in Depression
Depressed patients will have hearing tests and then be treated with up to three treatments
(i.e., Fluoxetine, Imipramine and Placebo) until remitted, to see whether test results
predict specific outcomes.
(i.e., Fluoxetine, Imipramine and Placebo) until remitted, to see whether test results
predict specific outcomes.
Preliminary data suggest that depressed patients with increased left hemispheric laterality
of perceptual processing are unlikely to improve during six weeks' treatment with placebo,
while being very responsive to either imipramine or fluoxetine. Depressed patients who do not
show evidence of poor right hemispheric functioning respond significantly more often to
placebo than those with poor right hemispheric functioning, and do not show an advantage of
drug over placebo. 100 depressed patients will be tested with verbal and nonverbal dichotic
tests, and then treated sequentially with Placebo, Fluoxetine and Imipramine until remitted.
Preferential hemisphere for auditory processing will be correlated with treatment outcome.
of perceptual processing are unlikely to improve during six weeks' treatment with placebo,
while being very responsive to either imipramine or fluoxetine. Depressed patients who do not
show evidence of poor right hemispheric functioning respond significantly more often to
placebo than those with poor right hemispheric functioning, and do not show an advantage of
drug over placebo. 100 depressed patients will be tested with verbal and nonverbal dichotic
tests, and then treated sequentially with Placebo, Fluoxetine and Imipramine until remitted.
Preferential hemisphere for auditory processing will be correlated with treatment outcome.
Inclusion Criteria:
- Ages between 18-65
- Meets DSM-IV criteria for current Major Depression, Dysthymia or Depression NOS
Exclusion Criteria:
- Known hearing impairment
- Active suicidal ideation (history of suicide attempts will be evaluated on a case by
case basis)
- HAMD > 20
- Current (past six months) alcohol and/or drug abuse or dependence
- Medical condition likely to require intervention contraindicated with study medication
(e.g., known arrhythmia likely to be exacerbated by Imipramine)
- Bipolar I
- Psychosis
- If currently taking antidepressants or mood stabilizers, cannot be off psychotropic
medication for 7 weeks (10 weeks for Prozac) or felt to require other psychiatric
medication (other than occasional sleep or Anxiety medication)
- Premenopausal women not using known effective birth control
- Not currently depressed (whether considered due to current treatment or not)
- Nonresponse to adequate trial of both study medications (i.e., > 4weeks on >
escitalopram 30 mg/d, and imipramine 200 mg/d); patients having an inadequate response
to one study medication could be enrolled and receive the other; patients having
responded to an adequate trial of either study medication would be offered a retrial;
also excluded will be subjects having non responded to an adequate trial with
citalopram (i.e., > 4 weeks on > citalopram 60 mg/d)
- Left-handed
We found this trial at
1
site
Click here to add this to my saved trials
